First-in-class therapy for autoimmune disease
Artax is discovering small molecules that target Nck, a key cytoplasmic adapter protein, recently discovered to play a key role in T-cell signalling and activation.
The Artax approach has the potential to reduce auto-immunity without affecting the ability of the immune system to respond to an infectious challenge.
CEO Joseph Lobacki
Advent Contact Alan Walts
Advent invested in the Series B in 2015.
Private Companies
Artax Biopharma Expands Company’s Scientific Advisory Board
Press Release. Company Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases. Cambridge, MA, November 15, 2022 - Artax Biopharma, Inc., a…
Read More
Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release. Close of $26 Million Funds Immunomodulation Candidate AX-158 Development Adds New Investors Eli Lilly and Company and Sound Bioventures Cambridge, MA, May 11, 2022 - Artax…
Read More
Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company’s First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release. The Phase 1 Trial, Expected to Conclude in 2022, Will Evaluate Safety, Exposure, and Pharmacokinetics of AX-158 in Healthy Volunteers AX-158, a Novel, Oral Small Molecule Immunomodulating…
Read More
